ANGLE’s patented Parsortix system provides the optimal solution for your laboratory to capture and harvest of circulating tumour cells (CTCs) and CTC clusters from whole blood samples.
Backed by >110 peer-reviewed publications from 42 independent cancer centres and spanning 24 cancer types, CTCs enriched by the Parsortix system are intact and label-free. They can be utilised in a wide variety of downstream analyses, providing critical insights in cancer research through proteomic, genomic, and transcriptomic testing.
Join our team at ACTC to learn more about how we are revealing the secrets of CTCs through multiomics and helping to advance precision monitoring in oncology. From optimised processing via the Parsortix system, through DNA dual analysis of CTC-DNA and ctDNA from the same sample we will demonstrate how multianalyte profiling may enable real-time monitoring of treatment response, resistance, and minimal residual disease.
Secure your 1:1 appointment below and learn more about:
Location
Thessaloniki, Greece, Makedonia Palace Hotel
Date
September 24-27, 2025
Request a meeting with the ANGLE team at the 7th ACTC meeting
ANGLE team